trial

Safety and Efficacy of Zicronapine in Patients With Schizophrenia

NCTId NCT01295372
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 160 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
160 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-04
Primary completion
2012-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ZicronapineRisperidone

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

24 total
Brno, CzechiaBrno, CzechiaKladno, CzechiaLiberec, CzechiaOlomouc, CzechiaPrague, CzechiaPrague, CzechiaSternberk, CzechiaPärnu, EstoniaTallinn, EstoniaTallinn, EstoniaTartu, Estonia

Linked catalysts

1
Safety and Efficacy of Zicronapine in Patients With Schizophrenia — primary completion2012-10

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE3
Primary Completion Date
2012-10
Status
COMPLETED
relationships
The graph out of here
drug
Zicronapine
drug
Risperidone
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication